Aligos Therapeutics, Inc. (NASDAQ:ALGS) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) have received a consensus rating of “Moderate Buy” from the five ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $41.50.

A number of research analysts have recently weighed in on ALGS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Aligos Therapeutics in a report on Monday, April 20th. Jefferies Financial Group upgraded Aligos Therapeutics to a “strong-buy” rating in a research report on Thursday, March 26th. Wall Street Zen upgraded Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Aligos Therapeutics in a research report on Wednesday, March 11th. Finally, Westpark Capital initiated coverage on Aligos Therapeutics in a research report on Thursday, March 26th. They issued a “buy” rating and a $48.00 target price on the stock.

Aligos Therapeutics Price Performance

Shares of NASDAQ:ALGS opened at $5.18 on Friday. The business’s 50-day moving average is $6.96 and its 200 day moving average is $7.96. Aligos Therapeutics has a 1 year low of $5.12 and a 1 year high of $13.69. The firm has a market capitalization of $32.06 million, a P/E ratio of -0.60 and a beta of 2.28.

Aligos Therapeutics (NASDAQ:ALGS) last announced its earnings results on Thursday, May 7th. The company reported ($2.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.29) by $0.08. The company had revenue of $2.83 million for the quarter, compared to analyst estimates of $0.25 million. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%. On average, analysts expect that Aligos Therapeutics will post -7.54 EPS for the current year.

Hedge Funds Weigh In On Aligos Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Rockefeller Capital Management L.P. raised its position in Aligos Therapeutics by 900.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after purchasing an additional 9,000 shares during the period. NorthCrest Asset Manangement LLC acquired a new stake in shares of Aligos Therapeutics in the third quarter valued at $98,000. Susquehanna International Group LLP acquired a new position in Aligos Therapeutics during the 3rd quarter worth $99,000. XTX Topco Ltd acquired a new position in Aligos Therapeutics during the 2nd quarter worth $100,000. Finally, HRT Financial LP acquired a new position in Aligos Therapeutics during the 4th quarter worth $106,000. Hedge funds and other institutional investors own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical?stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small?molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.